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Abstract 
Interaction between neoplastic cells and the microenvironment is critical in several cancers 
and plays a central role in multiple myeloma. Microenvironmental stimuli support plasma cells 
proliferation, survival, motility and can determine drug resistance. The network between 
plasma cells and surrounding cells is also responsible for increasing angiogenesis, 
unbalancing bone formation and bony lesions. The MET/HGF pathway is a key player of this 
interaction and has been found to be abnormally active in both malignant plasma cells and 
surrounding cells. Patients with abnormal MET and/or HGF levels usually experience a poor 
outcome even when treated with novel drugs. This review addresses the role of MET/HGF in 
the pathogenesis of myeloma and describes the role of MET/HGF signaling as a prognostic 
factor. The different techniques to detect MET/HGF abnormalities will also be examined. A 
final discussion on compounds targeting MET/HGF will summarize the current opportunities 
to introduce targeted therapy in myeloma patients. 
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The MET/HGF pathway 
 
The interaction of malignant cell with the microenvironment is a key feature of many cancers, 
determining growth, drug resistance and invasion. The network between different cells is 
based on both cell-to-cell interactions and soluble factors. The latters are produced in one cell 
and act paracrinally on neighboring ones, permitting change of information also in cells 
without a direct contact.[1] The role of the microenvironment is pivotal in multiple myeloma 
(MM), a blood cancer generating from bone marrow (BM) plasma cells (PCs) characterized by 
abnormal relationships with stromal cells, osteoclasts, osteoblasts and endothelial cells.[2] 
The Hepatocyte Growth Factor (HGF) is a key component of the network between different 
BM cells.  
 
HGF is a 90K multidomain glycoprotein physiologically produced and secreted by 
mesenchymal cells as a single-chain precursor (pro-HGF), which is then proteolytically 
cleaved to biologically active heterodimeric molecules by enzymes such as the serine 
protease HGF activator (HGFA).[3] The mature form consists of an α-chain (with a N-terminal 
domain and 4 kringle domains) and a β-chain (Serine proteases homology domain) linked by 
a disulfide bond. HGF is a potent angiogenic cytokine with ability to induce proliferation and 
migration of endothelial cells (EC).[4] In PCs HGF is strictly combined with surface protein 
CD138, the hallmark of myeloma cells. CD138 binds HGF and presents higher concentration 
of this factor to its receptor MET.[5] Physiologically HGF is able to modulate bone 
production/absorption and to regulate angiogenesis both directly and through modulation of 
other cytokines.  
 
The receptor of HGF is the tyrosine kinase (TK) MET, a surface protein encoded by a gene 
located on chromosome 7q21-31.(Fig.1) It has an extracellular α-chain linked to a 
transmembrane β-chain by a disulfide bridge. The extracellular portion is composed of three 
domain types: the Sema domain, a key structure for receptor binding; the plexin-semaphorin-
integrin (PSI) domain; and 4 immunoglobulin-plexin-transcription (IPT) domains. The 
extracellular part is linked to the intracellular portion that includes: a juxtamembrane region 
containing serine residues (S975, responsible for inhibition of MET activity) and tyrosine 
residues (Y1003, responsible of MET degradation); a catalytic region containing two catalytic 
tyrosines (Y1234 and Y1235, modulating MET enzymatic activity); a C-terminal region with 
two “docking” tyrosine residues (Y1349 and Y1356, able to bind SH2-containing intracellular 
effectors).[6]  
 
Following the binding of HGF with MET, a dimerization of the receptor leads to the trans-
phosphorylation of Y1234 and Y1235 (which increases the intrinsic catalytic activity of the 
kinase) followed by auto-phosphorylation of Y1349 and Y1356 (which recruits signal 
transducers to the receptor tail, thus activating different downstream pathways. The outcome 
of Met signaling includes several biological responses such as growth stimuli, reduction of 
apoptosis, increase in angiogenesis, ability to migrate and to infiltrate surrounding tissues.[7] 
Several adaptor proteins and kinase substrates are involved in transducing MET signal. The 
major substrate is considered to be Gab1, a multi-adaptor protein that can interact with MET 
both directly or via Grb2. This leads to the activation of several signaling cascade such as 
PI3K and AKT (promoting cell survival and migration) or Shp2 via Ras/ERK/MAPK (regulating 
proliferation and branching morphogenesis).[8-9] Similarly, the activation of Crk with Rap1 
and Rac can mediate cell motility and brancingh morphogenesis.[10] MET can also induce 
VEGF expression via recruitment of Shc.[11] 
 
Physiologically, the MET/HGF pathway has a crucial role in morphogenesis, while in the adult 
is involved in the development and regeneration of epithelial organs.[6] The MET/HGF 
pathway has also been implicated in development of hematopoietic cells; in fact, MET is 
expressed by a subset of hematopoietic precursor cells, whereas HGF is expressed by the 
bone marrow stromal cells (BMSCs).[12-13] Under normal conditions, MET/HGF activation is 
tightly regulated through paracrine ligand delivery, ligand activation at the target cell surface, 
and ligand-activated receptor internalization and degradation.[14] However, a deregulation of 
MET/HGF signalling is implicated in oncogenesis and progression of different solid 
malignancies, including colon, gastric, breast, ovarian, pancreatic, and lung tumors.[15-17] 
Aberrant MET/HGF pathway has also been implicated in the development and progression of 
B cell malignancies, including MM. 
 
Aberrant MET signaling can occur through different mechanisms, such as gene amplification, 
mutations, overexpression, excessive autocrine or paracrine ligand-mediated stimulation and 
interaction with other active cell-surface receptors.[18-19] In details: 
MET gene amplification: it causes overexpression of MET and has been reported in a number 
of human primary tumors, including gastric and esophageal carcinomas, medulloblastomas 
and liver metastases from colon carcinoma. In many of these cancers, patients carrying MET 
amplification showed a poor response to treatment and a dismal prognosis. In Non-Small Cell 
Lung Cancer (NSCLC) the presence of MET amplification causes resistance to EGFR 
inhibitors and characterizes patients with worst outcome.[20] 
MET mutations: mutations have been detected across the different MET domains, in 
particular its TK domains, deregulating either the activation or the degradation of the receptor. 
Several activating missense mutations of the MET gene have been identified as determining 
an aberrant signaling cascade in sporadic and hereditary papillary renal cancer, 
hepatocellular carcinoma, and gastric cancer.[21]  
MET overexpression: can be a result of transcriptional up-regulation due to upstream gene 
mutations or can be caused by hypoxia, inactivation of tumor suppression genes or loss of 
microRNAs.[3-22-23] MET overexpression can also be due to MET gene amplification. High 
levels of MET on the cell surface can lead to ligand-independent activation through 
spontaneous dimerization and phosphorylation. 
Abnormal HGF production: can be due to cancer cells or surrounding cells, sustaining cell 
growth in an autocrine or paracrine manner respectively. These mechanisms are present in 
MM as well as in many other cancers. HGF production can be further stimulated by hypoxic 
conditions via HIF-1α.[24] 
 
 
MET/HGF in the pathogenesis of multiple myeloma 
MM is the second most frequent blood cancer and derives from PCs, the late differentiation 
stage of B lymphocytes. Clonal PCs accumulate in the BM, produce intact (paraprotein) or 
partial (free light chain) immunoglobulines and are responsible for organ damage such as 
hypercalcaemia, kidney failure, anaemia and bony lesions. Many molecular alterations have 
been described in PCs, but very few of them have been considered as pathognomonic of MM. 
Chromosomal alterations (translocations involving the regulator of IgH locus and deletion of 
Ch13 and 17), mutations of oncogenes, abnormal expression of genes involved in lymphocyte 
maturation and miRNAs deregulation have been all involved in the pathogenesis and 
progression of MM.[25-26-27] Beside these, the signals produced by the microenvironment 
have always been considered as a key part of the disease, in particular of the progression 
from a premalignant phase to a symptomatic phase. Among all the cytokines stimulating MM 
growth, HGF is considered to be of pivotal importance because it is secreted both by PCs and 
BMSC.(Fig.2) 
 
The first observation of a possible role of MET/HGF in MM was done by Börset et al. in 1996 
investigating mRNA expression of HGF and MET in PCs and HGF protein content in the 
serum of MM patients. They observed that serum HGF levels were higher in MM patients than 
in healthy subjects (about 4 fold) and that MM PCs had concomitant expression of MET and 
HGF mRNA. This observation was peculiar of malignant PCs and was not found in PCs of 
MGUS patients, suggesting for the first time a possible autocrine loop sustaining MM cell 
growth.[28] Since then, several biological and clinical papers confirmed that aberrant 
expression of this pathway is common in MM. It was also shown that high serum levels of 
HGF activator (HGFA) are a distinguishing feature of BM of MM patients.[29-30]  
 
Beside the concomitant expression on MET and HGF in MM PCs (autocrine loop), HGF is 
secreted by stromal cells as well, confirming the presence of a paracrine HGF/MET 
communication. Notably, myeloma cells and stromal cells produce both HGFA and HGF, so 
the latter is processed in its active form.[31] This is an important step in HGF/MET signaling, 
allowing the MM cells to regulate the availability of HGF. Wader and colleagues showed with 
immunohistochemical analysis that MET exists in its phosphorylated state in a relevant 
number of MM patients indicating that HGF/MET system is active in MM patients in vivo; 
furthermore, it is expressed only in malignant PCs and MET levels increase along with 
disease progression.[32] HGF interacts with other surface molecules such as the heparin 
sulfate proteoglycan syndecan 1 (CD138), a hallmark of MM PCs. The high expression of 
Syndecan-1 on PCs increases HGF-mediated signaling, promoting cell survival and 
proliferation.[5] 
 
It has been clearly demonstrated that angiogenesis is increased in MM patients compared to 
patient with MGUS and it correlates with prognosis.[33] In agreement with the well known 
angiogenic properties, HGF signaling promotes angiogenesis and endothelial cell growth 
through direct interaction with MET (which is physiologically expressed in endothelial cells) or 
through an indirect cross-talk with the vascular endothelial growth factor (VEGF) and VEGF 
receptor (VEGFR) pathway. Indirectly, HGF can enhance the expression of VEGF and, 
similarly, can downregulate TSP-1 expression. The down-regulation of TSP-1 is mediated by 
different intracellular effectors such as MAPK, PI3-k or Stat3 according to the tissue analyzed. 
In addition to the MET/HGF loop found in the plasma cells, there is also a similar loop in the 
ECs of patients with MM and this can further modulate a network of cytokines resulting in 
enhancement of angiogenesis.[34]  
 
The VEGFA/VEGFR2 autocrine loop has been found in endothelial cells (ECs) obtained from 
BM with active MM.  Ferrucci et al. have shown that HGF/cMET pathway is only activated in 
multiple myeloma ECs of patients with active disease (diagnosis, refractory and relapse)[35]; 
moreover, the important increase of MET phosphorylation in ECs suggest that this pathway is 
constitutively activated in MM.[32] Therefore, the HGF/cMET autocrine loop may act as an 
additional angiogenesis amplifier for MM ECs. MET and HGF are expressed at a higher level 
in ECs of MM patient when compared with MGUS patients. This data has been confirmed at 
both mRNA and protein levels. As expected, MM ECs also secrete more HGF (2.5 fold on 
average) than MGUS EC as part of a self-sustaining loop.[35] 
 
It was demonstrated that HGF promotes the adhesion and migration of myeloma cells in vitro, 
implying that HGF/MET signaling could also be involved in the extravasation and homing of 
MM cells in vivo.[36-37-38] Interestingly, it was shown that MET signaling enhances the 
actions of interleukin-6 whose mechanism of action is the inhibition of MM cell apoptosis.[39] 
This suggests that MET signaling could also play a central role in MM biology by potentiating 
the effect of other myeloma growth factors. 
 
The balance between bone formation and bone resorption is lost in many cases of MM, 
resulting in bone destruction and the development of osteolytic lesions. During the whole 
history of the disease, more than 80% of patients experience bony lesions determining severe 
impairment in quality of life. Several observations indicate that MET/HGF pathway has a role 
in bone metabolism and MM-associated bone lesions.[40]  
 
MET is expressed on the osteoblast surface and HGF binding can inhibit osteoblastogenesis 
induced by bone morphogenetic protein (BMP). Standal et al. demonstrated that ALP 
(Alkaline Phosphatase, a specific marker of osteoblast activity) is reduced in vitro after HGF is 
added to the culture medium. HGF has been shown to also inhibit osteoblast-specific 
transcription factors Runx2 and Osterix and reduce the nuclear translocation of SMAD 1,5,8. 
These in vitro findings have been confirmed in biological samples of MM patients: a negative 
correlation has been found between HGF and ALP levels, supporting the role of HGF as an 
inhibitor of osteoblastogenesis.[41] mRNA HGF levels are also increased in MM PCs of 
patients with MM when compared with MGUS patients, and directly correlate with the 
presence of lytic bone lesions. Both MET and HGF mRNA were high in patients with 
advanced lytic bone lesions and a similar pattern was observed at the protein level, 
confirming in vivo the strong correlation between HGF and lytic lesions.[42] HGF has also 
been found to be produced by osteoclasts while MET receptor is located both at the surface 
of both osteoclasts and osteoblasts.[43] These observations suggest the possibility of an 
autocrine stimulation within osteoclasts and a concomitant paracrine stimulation in 
osteoblasts. Moreover, HGF stimulation induces IL-11 secretion from osteoblasts, which acts 
by stimulating osteoclast formation and suppressing bone formation.[44] Collectively, all these 
findings support the notion that the HGF/MET system contributes to bone erosion, while 
impairing bone formation. 
 
 
MET/HGF as prognostic factor in myeloma 
 
The observation that high HGF levels in serum of MM patients were able to predict poor 
response to treatment and short outcome was first reported more than 15 years ago.[45] Sera 
from 398 patients treated with MP were analyzed: 60% of patient with low HGF levels 
achieved a plateau phase, compared with only 46% of patients with high HGF and 27% of 
patients with extremely elevated HGF levels. This trend was confirmed on OS, with median 
OS of 32, 21 and 11 months for patients with low, high and very high HGF levels respectively. 
Similarly, the overexpression of MET mRNA in PCs of MM patients was also associated with 
low response to therapy and poor clinical outcome.[46] We investigated MET mRNA 
expression in 105 newly diagnosed MM patients treated with bortezomib-based therapy. The 
crude analysis of clinical outcome in the group of patients with high vs low MET mRNA 
expression (median value was used as a cutoff) showed a better prognosis in patients with 
low MET expression. In particular, the 4-year PFS was 39% in patients with low MET vs 20% 
in those with high MET and similarly the OS was 77% vs 51%. Interestingly, MET expression 
was independent of any other parameters used as prognostic factors in MM and these results 
were confirmed when MET expression was combined with β2-microglobulin: patients with 
both high MET mRNA and high β2-microglobulin had worst PFS and OS (8% and 32%) 
compared with the other patients (38% and 76% respectively). No differences were observed 
when patients were divided according to the mRNA expression of HGF. In 82 patients we 
were also able to quantify the MET copy numbers using FISH analysis. We have not found 
any monosomy of MET gene but in 30 patients (37%) we identified 3 or more copies of MET 
gene. There was no difference in MET mRNA expression values according to gene copy 
numbers, but patients carrying 4 copies (n=8) had a shorter survival compared to the other 
patients. The small numbers can only suggest copy number gains as a mechanism of growth 
advantage, thus underlying a more aggressive disease; however the independency of MET 
copy number and MET expression suggests that both these mechanisms can be implicated in 
determining partial response to therapy and poor outcome. 
 MET expression was found to be higher in MM than in MGUS but also higher in relapsed MM 
than in newly diagnosed MM. This implicates MET expression as a characteristic of 
recurrence and possibly as a causative event in progression of MM.[35] To confirm the link 
between HGF levels and MM, it was observed that HGF bone marrow plasma levels 
decrease with successful treatment responses and the serum levels of soluble form of MET (a 
negative regulator of HGF/MET activity) negatively correlate with disease stage.[47-48] 
 
 
MET/HGF and drug resistance 
 
MM is an incurable disease in most of the patients and the aggressiveness of PCs increases 
at each relapse. In fact drug resistance is the ultimate cause of disease progression due to 
the refractoriness to available treatments. MET has been described to be implicated in 
determining resistance to chemotherapy in several cancers including MM.[49-50] Several 
reports are suggesting that MET can be involved in drug resistance to therapy specifically 
targeting EGFR or angiogenesis; for instance, in EGFR mutant non-small cell lung carcinoma 
(NSCLC) amplification of MET was observed in 22% of tumors resistant to EGFR 
inhibitors.[20] 
 
The MET pathway is overexpressed in MM cell lines showing drug resistance as well as in 
primary samples from patients with relapse/refractory MM.[51] It has been reported that 
multidrug resistance MM cell line R5 is characterized by high levels of MET mRNA, MET 
protein and phospho-MET protein level. These findings are typical of the R5 cell line and are 
different from the chemo sensitive cell line RPMI-8226, which features normal MET levels. 
The authors also evaluated the role of SU11274, a highly specific MET inhibitor, in 
overcoming drug resistance in MM cells. SU11274 is able to specifically inhibit HGF-induced 
phospho-MET and its downstream signal.[52] Moschetta et al. tested the effects of SU11274 
in both cell lines and the reduction in phospho-MET was maximal in R5 while it was weak in 
RPMI-8226. This finding was observed also in another multiresistant cell line, MM.1R, 
compared to the sensitive cell line MM.1S. SU11274 determined a potent apoptosis in R5 cell 
lines (7 fold higher apoptosis compared to DMSO) but not in RPMI-8226 (only 2 fold higher). 
SU11274 was also able to overcome drug resistance to bortezomib, doxorubicine and 
melphalan in R5 cells. A similar observation was reported earlier with the U266 cell line, in 
which the knockdown of MET using small-interfering RNA (siRNA) increased cell sensitivity to 
chemotherapy agents.[53-54] The efficacy of SU1274 was confirmed in vivo in xenograft 
mouse models: a higher efficacy of the compound was observed in mice injected with the 
resistant R5 cell linethan in mice bearing xenografts of sensitive RPMI-8226. Trying to 
translate these observations into the clinical arena, authors treated primary 138+ cells with 
SU11274. The results showed more substantial effects in cells from relapsed/refractory MM 
patients compared with newly diagnosed ones, in line with the observation that phospho-MET 
was higher in the first group than in the latter. 
 The MET pathway has also recently been involved in carfilzomib resistance. Carfilzomib is a 
second-generation irreversible proteasome inhibitor recently introduced in the armamentarium 
of anti-MM compounds. Wang et al. generated several carfilzomib-resistant MM cell lines and 
investigated the differences in gene expression profiles between the wild type and the 
resistant cell lines. They found that suppression of MUC20 was consistently present in 
carfilzomib-resistant cell lines and was also a characteristic of bortezomib-resistant cell lines. 
The reduced expression of this gene (and protein) determines an increase in phospho-MET 
with activation of downstream signaling via STAT3 and ERK1-2. Thus the indirect activation 
of the MET pathway is one of the mechanisms likely responsible for resistance to either 
bortezomib or carfilzomib. When a MET inhibitor was used in combination with carfilzomib, it 
was able to restore carfilzomib sensitivity in previously resistant cell lines and in a murine 
model. A further validation to this is the observation that patients with high levels of MUC20 
had a better outcome (PFS and OS) than patients with low MUC20 levels treated with 
bortezomib.[55] 
 
These results have been confirmed in vivo by our study, showing that low MET mRNA 
expression in PCs identified patients with a better response to bortezomib-based 
treatment.[46] A consistent increase in MET expression has been observed in patients 
achieving a CR compared with those exhibiting stable disease. Median MET mRNA 
expression was 56.10 in patients achieving at least a VGPR but was 134.83 in those 
achieving only a PR or a SD. This finding suggests that different expression levels of MET 
can predict drug sensitivity and finally response to therapy. 
 
 
Techniques to evaluate MET/HGF in the diagnostic process 
 
Many studies have determined plasma and serum levels of HGF protein using an enzyme-
linked immunosorbent assay (ELISA) kit. Wader et al. have used this detection method also 
to determine the serum and plasma levels of a soluble form of MET in patients with MM 
(Wader et al. Eur J Haematol 2011). The serum and plasma samples are previously 
recovered and stored at -80°C and thawed at the moment of the analysis. Many samples can 
be analyzed in a single batch on the same day and a standard curve is generated for each set 
of samples assayed.[56-57]  
 
The distribution of HGF and MET protein in biopsies is usually investigated by 
immunohistochemistry (IHC). In IHC the starting materials are biopsies previously fixed in 
formalin, decalcified in ethylenediamine tetraacetic acid (EDTA) and embedded in paraffin 
wax. The immunohistochemical evaluation is performed using specific antibodies against 
MET, phospho-MET or HGF. The Nordic group has examined the expression of HGF and 
MET in 80 biopsies from patients with monoclonal plasma cell disease; only approximately 
10% of biopsies were not evaluable because high background. The biopsies evaluable 
showed a cytoplasmic staining for HGF in PCs while a membranous and/or cytoplasmic 
staining for MET was detected. However, there may be hurdles in discriminating a weak 
cytoplasmic/nuclear staining due to high background: indeed, the interpretation of sections 
with limited intensity and extent of staining may prove difficult when scoring positive versus 
negative samples.[32-42] In IHC the expression of MET is a hallmark of MM PCs and it is 
absent in PC of healthy subjects or in MGUS patients. This specific MET expression can be 
useful in distinguishing malignant from non-malignant PCs. 
 
MET, phosphor-MET and HGF can also be assessed using western blot: the cell lysates are 
probed with primary antibodies and developed with a conjugated secondary antibodies. 
However the needing of large amounts of cells is still a limit to use routinely this approach in 
clinical practice.[39] 
 
A faster method employed to evaluate the intracellular or cell surface expression levels of 
HGF, MET and phospho-MET protein is flow cytometry. Viable cells are labeled with a 
fluorescein-conjugated monoclonal antibody and subsequently analyzed using a flow 
cytometer. Like western blotting, this method is used to evaluate the expression mostly in MM 
cell lines since often the amounts of primary cells are limited.[39-57] Moreover, the use of flow 
cytometry is already part of diagnostic procedure in some institutions and only minimal 
arrangements are required to include this analysis into the existing workflow. 
 
Fluorescent in situ hybridization (FISH) can be used to determine HGF and MET gene copy 
number. A dual-color probe is employed and FISH results can be interpreted with different 
scoring systems depending on the cut-off chosen.[58-59] We performed a specific 
investigation of MET gene copy number in 82 MM patients and the ratio between MET gene 
and control gene was used to define MET status.[46] This was the first paper investigating the 
presence of MET amplification in MM, although a higher number of patients are required in 
order to set the specific cut-off in this particular disease. 
 
A more sensitive method to evaluate the expression levels of HGF and MET is transcript 
quantification by real-time reverse transcription-polymerase chain reaction (qRT-PCR). In this 
method, RNA is transcribed into complementary DNA (cDNA) by reverse transcriptase from 
total RNA or messenger RNA (mRNA) and a relative quantification is performed using a pair 
of unlabeled PCR primers and a probe with a reporter at the 5' end, and a quencher at the 3' 
end. For optimal results it is important that PCR primers and probes are designed carefully. 
Gene expression levels in real-time PCR experiments are normalized using an endogenous 
(“housekeeping”) control gene; samples can be frozen and subsequently analized in banch in 
the same run on the same day to reduce costs and time and to increase accuracy.[36-51-46] 
 
Mutational analysis of MET and HGF may be investigated with conventional capillary 
electrophoresis (Sanger sequencing) or next-generation sequencing technology, which is 
endowed with greater sensitivity. This technique has not yet been used for studies of MET 
and HGF in MM but it has been used for human solid cancers. It allows the analysis of 
multiple genes, the study of the MET/HGF pathway at the same time and requires limited 
amounts of DNA.[60] 
 
 
MET/HGF as targets of anti-Myeloma therapy 
 
The recurrence of MET/HGF abnormalities in virtually all cancers has sustained the 
development of several compounds aiming to interrupt this aberrant signal. Several strategies 
have been proposed to block the abnormal activation of the MET/HGF pathway and to 
interrupt the activation of intracellular cascades causing tumor aggressiveness and growth. 
The drugs under investigation can be divided in two large groups: biological drugs and TK 
inhibitors. The first are protein-based agents targeting mainly the extracellular region of the 
cells and can be monoclonal antibodies or antagonists of HGF. MET antagonists are 
truncated molecules similar to HGF; they bind MET causing only partial or minimal activation 
of intracellular pathway and phenotypic cell changes. Although preliminary results are 
interesting, their action is limited to those cells with an increase in ligand-dependent 
stimulation. Monoclonal Abs binds MET occupying the HGF binding site and causing 
blockage of phosphorylation and inhibition of downstream pathway. Similarly to MET 
antagonists, the mAbs are promising when abnormal Met activation is due to an increase in 
ligand-dependent stimulation. They are very specific and with a long half-life, but they can 
have suboptimal cell penetration; moreover, the production costs are high and their required 
intra venous administration.  
 
On the contrary the TK inhibitors are small molecules able to interact with the intracellular part 
of the receptor and mainly block the kinase following HGF ligand stimulation or constitutive 
activation. They are usually oral and differentiate each other for the binding site or for the 
level of interaction with downstream pathways. One of the first TK inhibitors tested in vitro on 
MM cells has been PHA-665752. It is an ATP-competitive inhibitor selective for MET able to 
inhibit the activation of several downstream transducers, including  the binding of Gab1 with 
MET and the HGF-mediated stimulation of Akt.[37] PHA-665752 has been shown to be able 
to reduce proliferation and adhesion to fibronectin both in MM cell lines and in primary 
selected PCs. The observation that it can inhibit the production of IL-11 suggested a possible 
role in disrupting a stimulus of bone damage. 
 
The compounds that have been tested in vitro or in vivo in MM are described in detail below 
and are summarized in Table 2. 
 
Tivantinib (ARQ197) 
It is a highly selective non ATP-competitive inhibitor of MET. It is an oral compound that 
inhibits both constitutive and ligand-induced phosphorylation of MET and downstream 
effectors. Interestingly, ARQ197 action was observed in cell lines with different mechanisms 
of MET dysregulation such as MET gene amplification in MKN45 and ligand-dependent MET 
activity in MDA-MB-231. Although the role of Tivantinib as a specific Met inhibitor has been 
recently questioned, in vitro results have been confirmed in vivo in xenograft mouse models, 
with reduction in tumor growth after treatment with this compound.[61] These results 
suggested that the higher the levels of MET protein and mRNA, the stronger was the efficacy 
of ARQ197. This observation underlines how important is the pre-treatment evaluation in 
order to identify patient that can benefit from this treatment.[62] A Phase II trial is ongoing to 
test the efficacy and safety of ARQ197 in relapsed/refractory MM patients. Results have been 
presented on 16 patients treated with a median of 3 cycles of therapy. Grade 3-4 toxicity 
included fatigue (31%), neutropenia (25%), syncope, infection and pain (all 13% G3). One out 
of 16 patients reported anal fissure, cough, fatigue, hypertension and pulmonary embolism 
G3. A G1-2 fatigue was reported in 94% of patients and diarrhea in 38%. A Stable disease 
(SD) was reported in 4/11 of evaluable patients (36%) and it was maintained up to 11 
cycles.[63] 
 
Ficlatuzumab 
It is a humanized HGF inhibitory monoclonal antibody able to neutralize the binding between 
HGF and MET thus blocking MET-phosphorylation and downstream intracellular cascades. 
After promising in vivo experiments in xenograft models, it was evaluated in a Phase I trial 
enrolling 41 patients with refractory solid cancer or MM. Twenty one patients received 
Ficlatuzumab every 14 days as monotherapy and 13 patients in combination with erlotinib 
(EGFR inhibitor) administered on day 1. The G3-4 toxicity was mainly hypokalaemia (15%), 
peripheral oedema (7%), diarrhea/vomiting (7%) and fatigue (4%). The best overall response 
was SD achieved in 44% of patients with a median duration of 5.5 months. The 
recommended dose for a Phase II trial was identified as 20 mg/Kg every 14 days.[64]  
 
Cabozantinib (XL184)  
It is an inhibitor of several tyrosine kinases including MET, VEGFR2, RET, TYROL3 and AXL. 
It has been tested in a syngeneic 5TGM1 mouse model of MM with the primary aim of 
investigating its activity on bone lesions. MM cells were inoculated IV in the mice and the lytic 
lesions were detected by radiography. Interestingly, cabozantinib showed bone protective 
effects including reduction in total area of osteolysis, TRACP 5b levels and of osteoclast 
number. All these effects were higher in cabozantinib-treated mice than in bortezomib-treated 
mice. When these drugs were administered simultaneously, an increase in OS was observed 
( median OS: 43 days with bortezomib, 48 days with cabozantinib, and 55 days with both.[65] 
 
Amuvatinib (MP470) 
It is a carbothioamide able to inhibit MET, cKIT and PDGF. It is an orally available drug and 
has been studied in in vitro models of myeloma. It has been shown to be able to induce cell 
death in 6/8 of primary CD138+ cells of patients with myeloma, reducing the MET 
phosphorylation on Tyr 1234/1235 by approximately 50%. This effect was observed only in 
CD138+ cells and not in the CD138- fraction, which experienced only minimal cell death 
(<10%) when cultured in presence of amuvatinib. This observation suggests that the non-
malignant bone marrow cells are not effected by amuvatinib action because they have very 
low level of p-MET. In the U266 myeloma cell line (expressing high level of HGF), amuvatinib 
was able to cause cell-cycle arrest in G1, decrease thymidine incorporation and cause 
increase in cell death. The cell death process was caspase-mediated and, again, was 
observed only in U266 cell line. When a cell line expressing very low levels of HGF and MET 
was used (RPMI-8226/S) only minor apoptosis induction was observed. When the 
downstream targets of MET were investigated, both ERK1/2 and AKT signal were 
inhibited.[57] 
 
SU11274 
It is a MET inhibitor tested to evaluate its ability to reduce endothelial cell growth. When ECs 
of MM patients were cultured with anti-HGF or anti-MET Abs, the viability and the proliferation 
was not impaired. However the migration activity was markedly impaired, up to 45% despite 
concomitant stimulation by angiogenic factors.[35] Similar results have been obtained with 
SU11274. Interestingly, a strong synergistic antiangiogenic effect was observed when 
SU11274 was added to bortezomib or lenalidomide: both inhibition of mesh areas and 
reduction of vessel length were doubled in the presence of of SU11274. The treatment with 
SU11274 also modified some angiogenesis-related cytokines, with a decrease of pro-
angiogenic cues (SERPIN E1, CXCL16 and MCP-1) and an increase in the negative regulator 
SERPIN F1. These results suggest that SU11274 could interfere also with MM angiogenesis 
on top of its direct anti MM effects against PC. 
 
NK4 
It is an antagonist of HGF, composed of the NH2-terminal hairpin loop and the 4 kringle 
domains of HGF. It competes with HGF for MET binding but it does not cause any MET 
phosphorylation after binding. It is able to inhibit HGF-induced proliferation and to promote 
apoptosis of PCs both directly (acting on ERK1/2, STAT3 and AKT-1 pathways) and indirectly 
via angiogenesis inhibition. These observations were first obtained in cell lines and were 
confirmed in primary cells of MM and xenograft mouse models. Interestingly, the efficacy of 
NK4 has been observed also in non-HGF producing cells growing in an HGF free medium. 
Moreover, the histological examination of tumor tissues derived from mouse xenografts 
revealed that NK4 is able to reduce the vascularization around MM cells, confirming an 
indirect way of reducing cell growth via inhibition of angiogenesis.[66] 
 
Anti MET Nanobody: 
Nanobodies are proteins based on the smallest functional fragments of heavy chain 
antibodies and can be directed against different antigens. In pioneering work, Slørdahl et al 
demonstrated that an anti-MET nanobody is able to specifically bind MET and inhibit HGF-
driven phosphorylation as well as activation of downstream signals, in particular the MAPK 
pathway and Akt. Moreover, the nanobody can reduce the adhesion of MM cells (adhesion is 
well-known mechanism of drug resistance) and can intercept the inhibitory effect of HGF on 
osteoblastogenesis. These results confirm that targeting MET/HGF can cause anti MM effects 
non only in malignant plasma cells but also in the surrounding cells, which contribute to bone 
disease and drug resistance.[67] 
 
MP0250 
It is a bispecific DARP able to inhibit both HGF and VEGF. It has been tested in vitro as 
monotherapy and in combination with bortezomib. Blocking HGF and VEGF is sufficient to 
stop a positive feedback for PC growth and to reduce bone destruction. In an orthotopic 
murine model with primary myeloma cells implanted in the bone marrow, treatment with 
MP0250 and bortezomib reduced bone lysis, as measured with micro-CT and X-ray. Albeit 
very preliminary, this observation suggests a possible synergistic effect of MP0250 without 
any additional toxicity.[68] 
 
Beside these compounds that have been tested in MM, many other small-molecule inhibitors 
(such as crizotinib and golvatinib) and mAbs (such as rilotumumab and onartuzumab) are 
under investigation in other cancers. Overall, the compounds targeting MET/HGF have shown 
an acceptable toxicity profile, with side effects that are usually different from other anti 
myeloma drugs 
 
 
Conclusions 
 
The pathogenesis and progression of MM is very complex and only partially known. Several 
molecular alterations in PCs have been reported, as well as a key role of stromal cells, 
angiogenesis and the bone microenvironment. The survival and growth of myeloma cells are 
dependent on the presence of a permissive microenvironment able to support cell 
proliferation and protect PCs from drug toxicities. The possibility to reduce (or stop) the 
crosstalk between PCs and microenvironment is an appealing approach in MM. 
 
Among several pathways, MET/HGF has been reported to be a pivotal one . Indeed, the 
HGF/MET axis is abnormally active in both PCs and the microenvironment and a positive 
feedback between these two entities has clearly been documented resulting in cell growth, 
invasion, bone disease and drug resistance. MET/HGF may be a promising target also to 
reduce angiogenesis in MM patients. MET is constitutively activated, overexpressed or 
stimulated by HGF in a fraction of MM patients and sustained MET stimulation has been 
reported in several solid and hematological cancer as a hallmark of aggressive disease. 
Targeting the MET/HGF pathway could break the crosstalk between myeloma cells and the 
surrounding environment, reducing drug resistance and increasing response to treatment. 
This could be of particular importance in relapsed/refractory patients where the MET/HGF 
system is frequently deregulated.  
 
Some issues need to be solved before considering this pathway a viable therapeutic  target in 
MM. The selection of patients is still the major obstruction and the challenge will be to 
accurately identify patients that can benefit from such specific therapy. The results of initial 
clinical trials are showing that unfortunately not all patients with an abnormal MET/HGF 
pathway will respond to the treatment (primary resistance) highlighting the importance of 
biomarkers to pinpoint the patients with a higher chance of responding to MET/HGF inhibitors. 
Specific tests to characterize the MET/HGF pathway in each MM patient need to be 
developed as companion diagnostics in order to identify potential responders. This is a 
growing concept in medicine and oncology in particular, but becomes crucial in such a 
specific treatment approach as TK inhibitors.  
 
Moreover, even responding patients will develop drug resistance along treatment (secondary 
resistance). The reasons for acquired resistance are manifold, but they all rely on the 
plasticity of oncogene activity and the presence of several crosstalks within the intracellular 
pathways It is thus critical to find out what are the mechanisms of acquired resistance in order 
to prevent, delay, or early detect them. Mutations in the target molecule is a well-known 
escape mechanism allowing cells to be refractory to a treatment; similarly, the activation of 
parallel signaling pathway enables cells to elude the consequences of target blockade. In the 
same vein, longitudinal monitoring of the MET/HGF pathway is mandatory to timely detect 
any molecular changes that can lead to resistance to therapy. All these aspects (and 
limitations) are particularly critical in MM, a disease with a high degree of heterogeneity and 
several ways to display drug resistance. Thus, the targeting of the MET/HGF system needs to 
be included within a therapeutic approach that also incorporates less specific drugs such as 
IMiDs or proteasome inhibitors.  
 
The timing of anti MET/HGF treatment should be carefully evaluated as well. It has been 
reported, as expected, that patients with relapse/refractory (R/R) MM have higher levels of 
MET, a condition that likely predicts response to HGF/MET inhibitors; however, such patients 
are expected to bear tumors with a higher mutational load and with many more genetic 
abnormalities than early-stage patients, which might require combinatorial approaches 
against HGF/MET and other driver oncogenic lesions Further clinical observations are 
required before the best timing will be identified. 
 
Overall, strong evidence supports the observation that abnormal HGF/MET activity has a key 
role in MM pathogenesis and such deregulation characterizes patients with suboptimal 
response to therapy and poor outcome. Promising results are coming from early clinical trials 
testing anti MET/HGF compounds in cancer in general, confirming their efficacy and their 
ability to restore chemotherapy sensitivity while displaying acceptable safety profiles. 
 
 
Five year view 
 
Targeted therapies have revolutionized the way cancer is treated, increasing significantly the 
life expectancy and the quality of life of patients. Due to the heterogeneity of abnormal 
signals, in MM the therapy is mainly based on compounds with a broad spectrum of actions. 
The inclusion on Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI) in all 
regimens led to a dramatic increase in PFS and OS in the last years, but both these classes 
of drugs act in a non-specific manner. 
 
The possibility of adding a compound targeting an abnormal pathway is fascinating, but 
several steps are required for patients to receive clinical benefit. One critical issue to be faced 
in next few years will be the identification of biomarkers able to enrich for potential responders 
to anti MET/HGF treatment. MET/HGF is a key player in sustaining MM cell growth and in 
causing organ damage; however, a sensitive and reliable test to evaluate the MET/HGF 
pathway remains unavailable. Several techniques are under investigation and can be 
included in the diagnostic process, but the ability to correctly identify the patients for targeted 
therapy is still suboptimal. 
 
In the last few years several compounds reached the advanced clinical phase of investigation 
(Phase II-III) in MM. Some of them are novel drugs of already existing class (IMiDs as 
pomalidomide or PI as carfilzomib and ixazomib) and some are new classes of drugs such as 
monoclonal antibodies. Several other new molecules are under investigation, with the 
promise to enrich the therapeutic armamentarium to treat patients with MM with specific drugs 
targeting abnormal pathways.  
 
This scenario will have two major implications: the first is the possibility to inhibit abnormally 
active pathways critical for MM growth, the second is the need of a correct identification of 
patients suitable to receive this specific treatment. The first point is important in MM because 
several pathways can be involved in sustaining cell growth and within such pathways the 
MET/HGF is one of the most important. Inhibition of this pathway has been reported to reduce 
cell growth and increase drug sensitivity. Several MET inhibitors are currently available and 
further characterization of their mechanisms of action will allow optimizing their use in 
myeloma patients.[69]  
 
The real challenge will be the patient selection process, with the identification of a reliable 
technique to evaluate MET/HGF status and select patients who will benefit from MET 
inhibitors. The importance of this endeavor has been highlighted in several papers and this 
issue is still a barrier to widespread use of anti MET/HGF compounds in the treatment of 
cancer. However, the availability of several compounds targeting this pathway in virtually all 
cancers will speed up the process to select a reliable marker and include it into clinical trials. 
If the results available so far are confirmed on larger number of patients, in the next few years 
a new class of drugs will be available for cancer treatment in general and in particular for MM 
patients. 
 
  
Key issues 
- MET/HGF pathway is abnormal in MM PCs and plays a role in its pathogenesis 
- Abnormalities in MET/HGF increase angiogenesis and cause bone disease 
- MET/HGF abnormalities usually characterize patients with poor prognosis 
- Targeting MET/HGF results in cell death and can attenuate resistance to 
chemotherapy 
- A reliable marker of sensitivity to anti MET/HGF treatment is needed to identify patients 
expected to benefit from anti MET therapy 
- Biomarker analysis should require easy standard procedures to become a routine 
companion diagnostic for MM patients 
- Compounds targeting the MET/HGF pathway will likely be used in combination with 
chemotherapy agents 
- Early identification of resistance to treatment will be critical in patients treated with MET 
inhibitors 
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Table 1: Techniques to evaluate MET/HGF  
 
 
Methods Advantages Disadvantages 
ELISA
• Use of stored samples             
• High-throughput                          
• Less labor intensive
• Requires a standard curve                                   
• Detection of only one target
IMMUNOHISTOCHEMISTRY
• Not requires viable cells 
• Possible to detect two targets 
simultaneously
• Non specific background                    
• Labor intensive
WESTERN BLOTTING
• Not requires viable cells 
• Detection of several targets
• Requires high skill level of the 
experimenter                 
• Labor intensive
FLOW CYTOMETRY
• Measures several antigens 
simultaneously                            
• High sensibility   
• Requires high skill level of the 
experimenter             
• Requires viable cells         
• Requires an appropriate amount 
of cells                         
• High cost      
FISH
• Not requires viable cells • Labor intensive                         
• Different scoring systems
qRT-PCR
• High sensibility                               
• High-throughput   
• Primers and probes design
NGS
• Requires low amounts of DNA                               
• Analysis of multiple genes   
• High sensibility                         
• High-throughput     
• Requires skill bioinformatics                   
• High cost               
ELISA= enzyme-linked immunosorbent assay; FISH= fluorescent in situ hybridization; qRT-PCR= real-
time reverse transcription-polymerase chain reaction; NGS= next-generation sequencing 
Table 2: anti MET/HGF compounds 
 
Drug Name 
Mechanism 
of action 
Target 
Phase of 
investigation 
Results Reference 
PHA-665752 TK inhibitor MET 
preclinical                                  
(cell lines, 
primary cells) 
inhibition of MET 
phosphorilation and 
downstream signalling. 
Blockage of proliferation 
in primary myeloma cells. 
37 
Tivantinib 
(ARQ197) 
TK inhibitor MET Phase II 
16 R/R MM patients.                   
G3-4 toxicity: neutropenia, 
syncope, infection, pain.            
Response: SD in 4/11 
patients 
63 
Ficlatuzumab 
HGF 
antagonist 
HGF Phase I 
41 patients (4 with MM).              
G3-4 toxicity: fatigue, 
peripheral oedema, 
diarrhoea, vomiting, 
hypokalaemia.                  
Reponse: SD in 12/24 
patients 
64 
Cabozantinib 
(XL184) 
TK inhibitor 
MET, 
VEGFR2, 
RET, TAM 
family 
Preclinical                                      
(xenograft 
mouse model) 
bone protection action 
and anti tumor effects. Its 
activity is synergistic with 
bortezomib  
65 
Amuvatinib 
(MP470) 
TK inhibitor 
MET, cKIT, 
PDGFR 
preclinical                                  
(cell lines, 
primary cells) 
inhibition of MET 
phosphorilation, induction 
of apoptosis and growth 
inhibiton in primary 
myeloma cells 
57 
SU11274 TK inhibitor MET 
preclinical                                  
(cell lines, 
primary cells, 
mouse model) 
inhibition of endotelial 
cells proliferation, 
reduction of angiogenesis-
related cytokines, 
synergistic effect with 
bortezomib 
35 
NK4 
HGF 
antagonist 
HGF 
preclinical                                  
(cell lines, 
primary cells, 
mouse model) 
inhibit growth of myeloma 
cells in vitro and in 
xenograft mouse model. 
Reduction of 
angiogenesis substained 
by HGF. 
66 
Anti MET 
Nanobody 
anti-MET Abs MET 
preclinical                                  
(cell lines, 
primary cells) 
inhibition of migration, 
adhesison and 
proliferation of myeloma 
cells, blockage of HGF-
mediated inhibition of 
osteoblastogenesis 
67 
 
 
Fig 1: MET/HGF pathway and druggable targets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2: role of MET/HGF in the relationship between plasma cells – bone cells and    
          Angiogenesis 
 
